How Much Does an Aromatase Inhibitor Reduce Risk of Recurrence?

Aromatase inhibitors lower the risk of breast cancer recurrence by roughly 20 to 35 percent compared with the older standard drug tamoxifen, depending on the time window measured and the patient population. A large meta-analysis pooling data from nearly 10,000 postmenopausal women found an absolute drop of about 3 percentage points in five-year recurrence rates. That gap sounds modest until you consider it in the context of a disease where even small absolute gains translate to thousands of lives, and that the benefit grows with longer follow-up. The size of the benefit, however, depends on factors that are worth understanding in detail.

What the Major Trials Actually Show

The clearest picture of aromatase inhibitor efficacy comes from head-to-head comparisons against tamoxifen, the drug that dominated hormonal breast cancer treatment for decades. A meta-analysis published in the Journal of Clinical Oncology pooled data from trials comparing five years of an aromatase inhibitor with five years of tamoxifen. At five years, the recurrence rate was about 9.6 percent in the aromatase inhibitor group versus 12.6 percent in the tamoxifen group, an absolute difference of roughly 3 percentage points.¹

A later and larger patient-level meta-analysis in The Lancet provided more granular data. During the first year of treatment, aromatase inhibitors cut recurrence risk by about 36 percent relative to tamoxifen. During years two through four, the reduction was about 20 percent. After year five, the gap between the two drugs narrowed and was no longer statistically clear. By ten years, breast cancer mortality was about 12 percent in the aromatase inhibitor group and about 14 percent with tamoxifen, a meaningful reduction that translated to roughly a 15 percent lower chance of dying from the disease.²

The pattern across these trials is consistent: aromatase inhibitors offer the biggest advantage during active treatment, particularly in the first few years. The effect fades over time once both groups have stopped taking their medication. That observation naturally led researchers to ask whether keeping patients on an aromatase inhibitor for longer might push the benefit further.

What Happens When Treatment Goes Beyond Five Years

The standard course for an aromatase inhibitor is five years. Several trials have tested whether extending that to ten years adds further protection. In the MA.17R trial, women who had already completed about five years of aromatase inhibitor therapy were randomly assigned to continue letrozole or switch to a placebo for another five years. The five-year disease-free survival rate was 95 percent in the letrozole group compared with 91 percent in the placebo group. The risk of cancer in the opposite breast was cut roughly in half with continued treatment.³

A 2025 individual patient data meta-analysis in The Lancet pulled together results from multiple trials of extended aromatase inhibitor therapy. After a median follow-up of about eight years, five additional years of treatment reduced recurrence by roughly 29 percent. The absolute difference was about 3.6 percentage points, from about 15 percent recurrence with placebo down to roughly 12 percent with extended therapy. Distant recurrence, the type most likely to threaten survival, also dropped. Yet breast cancer mortality was not significantly lower, at least within the follow-up window available.⁴

That gap between reduced recurrence and no clear mortality benefit is one of the more frustrating patterns in this field. Extended therapy clearly prevents some cancers from coming back. Whether that prevention ultimately translates into longer life is still uncertain, partly because hormone-receptor-positive breast cancers can recur very late, sometimes a decade or more after diagnosis. Follow-up periods may simply not be long enough yet to capture a mortality benefit from the recurrences that were averted.

Aromatase Inhibitors in Younger Women

Aromatase inhibitors were originally developed for postmenopausal women because the drugs work by blocking the enzyme that converts androgens into estrogen in fat, muscle, and other tissues outside the ovaries. In premenopausal women, the ovaries are the dominant estrogen source, and an aromatase inhibitor alone cannot overcome that production. To use these drugs in younger patients, doctors combine them with ovarian suppression, either via medication or surgery.

A patient-level meta-analysis of more than 7,000 premenopausal women compared aromatase inhibitors plus ovarian suppression against tamoxifen plus ovarian suppression. The aromatase inhibitor combination reduced recurrence by about 21 percent overall. During the first four years, when treatments differed, the reduction was about 32 percent. The five-year absolute difference in recurrence was roughly 3 percentage points, from about 10 percent with tamoxifen down to about 7 percent with the aromatase inhibitor.⁵

A landmark individual trial, the SOFT/TEXT analysis, showed a similar pattern. At five years, about 93 percent of women on exemestane plus ovarian suppression were free from breast cancer events, compared with about 89 percent of those on tamoxifen plus ovarian suppression.⁶ For younger women with higher-risk cancers, the absolute benefit can be considerably larger, which is why oncologists are increasingly recommending this combination for premenopausal patients with aggressive features.

How These Drugs Actually Work

Aromatase is the enzyme responsible for the final step in estrogen production. It converts androgens, hormones the body produces from the adrenal glands and ovaries, into estradiol and estrone, the primary estrogens.⁷ By blocking aromatase, these drugs starve hormone-receptor-positive tumors of the estrogen they depend on for growth. They lower circulating estrogen as well as the estrogen available within tissues where tumors reside.⁸

This is a fundamentally different strategy from tamoxifen, which does not reduce estrogen levels at all. Tamoxifen blocks estrogen from reaching the receptor on cancer cells. The clinical difference matters because aromatase inhibitors are generally more effective but also come with a distinct side-effect profile tied to very low estrogen throughout the body.

Side Effects That Undermine the Benefit

On paper, aromatase inhibitors offer a clear advantage over tamoxifen. In practice, that advantage shrinks if patients stop taking the medication early. And early discontinuation is common, driven primarily by musculoskeletal pain. About half of patients report new or worsening joint pain within the first year on an aromatase inhibitor. Roughly 30 percent stop taking the drug after one year, and only about half to two-thirds remain fully compliant after three years.⁹

The joint pain can range from mild stiffness to debilitating aches in the hands, knees, and hips. It tends to appear within the first few months and often worsens before it stabilizes. Exercise, which can feel counterintuitive when your joints hurt, is one of the better-studied interventions. Switching between different aromatase inhibitors sometimes helps as well, since the three available drugs (anastrozole, letrozole, and exemestane) can cause different symptom profiles in different people.¹⁰

Bone loss is the other major concern. By depleting estrogen, aromatase inhibitors accelerate the thinning of bone that occurs after menopause. Guidelines recommend that all patients starting an aromatase inhibitor get a baseline bone density scan, take calcium and vitamin D supplements, and engage in weight-bearing exercise. Patients with already-low bone density or additional fracture risk factors may need bone-protecting medications alongside their cancer treatment.¹¹

The Cardiovascular Trade-Off

One complication that is underappreciated involves heart health. Tamoxifen has a mild protective effect on the cardiovascular system, which means comparing aromatase inhibitors against tamoxifen makes the aromatase inhibitors look worse on heart outcomes than they might look compared with no treatment at all. A systematic review and meta-analysis found that aromatase inhibitors (alone or sequenced with tamoxifen) carried about a 16 percent higher risk of cardiovascular events compared with tamoxifen alone.¹²

A population-based study put finer numbers on this. Compared with tamoxifen users, women on aromatase inhibitors had roughly double the rate of heart failure and about 50 percent higher cardiovascular mortality.¹³ These numbers should be interpreted carefully. They compare two active drugs, not drug versus nothing. And the absolute rates are still relatively low. For most patients, the cancer-recurrence benefit outweighs the cardiovascular risk. But for women with pre-existing heart disease, the choice between tamoxifen and an aromatase inhibitor deserves a genuine conversation about both sides of the ledger.

Why Body Weight Can Matter

There is a biological reason to suspect that aromatase inhibitors might work less well in women with higher body weight. Fat tissue is one of the main sites where aromatase converts androgens to estrogen after menopause. More fat tissue means more aromatase activity and higher baseline estrogen levels. The concern is that a standard dose of the drug may not suppress estrogen as completely in a larger person.¹⁴

Research on this question has shown that after three months of treatment, estrogen levels tend to be somewhat higher in obese patients than in non-obese patients, though the difference in one study did not reach statistical significance. Hormone markers that indicate the degree of estrogen suppression (like FSH levels) were significantly different, however, suggesting incomplete suppression in the heavier group.¹⁵ And separate clinical data have found that higher body mass combined with negative progesterone receptor status is an independent predictor of shorter time to recurrence in patients on aromatase inhibitors.¹⁶

This does not mean aromatase inhibitors fail in larger patients. They still suppress estrogen substantially. But the degree of suppression appears to be somewhat less complete, which may translate into modestly reduced protection. It is an active area of investigation, and no guidelines currently recommend dose adjustments based on weight.

When the Cancer Stops Responding

Some hormone-receptor-positive cancers eventually develop resistance to aromatase inhibitors. One of the best-understood mechanisms involves mutations in the ESR1 gene, which provides the blueprint for the estrogen receptor itself. These mutations are found in roughly 20 percent of patients with metastatic hormone-receptor-positive breast cancer who have received endocrine therapy.¹⁷

What these mutations do is striking: they make the estrogen receptor active even without estrogen present. Blocking estrogen production with an aromatase inhibitor becomes far less effective when the cancer cell has rewired its growth signals to no longer need the hormone. In tumors with ESR1 mutations, the expression of estrogen-responsive genes that drive cell growth was about sevenfold higher than in tumors without the mutations.¹⁸ These mutations are rare in untreated cancers and appear to emerge under the selective pressure of treatment.¹⁹

Understanding resistance is practically relevant because newer drugs, such as CDK4/6 inhibitors and next-generation estrogen receptor degraders, have been developed specifically to address or delay this kind of resistance. When a recurrence happens despite aromatase inhibitor therapy, the treatment plan shifts accordingly.

Use Before Surgery

Aromatase inhibitors are not just used after surgery. In some cases, they are given before surgery (neoadjuvant therapy) to shrink a tumor and make it operable or to allow breast-conserving surgery rather than mastectomy. All three approved aromatase inhibitors have been shown to improve breast-conservation rates in this setting.²⁰ A multicenter trial confirmed that neoadjuvant aromatase inhibitor therapy improved operability, though it noted considerable variability in how individual tumors responded.²¹

Neoadjuvant aromatase inhibitor therapy tends to work best in strongly hormone-receptor-positive cancers in postmenopausal women. The typical course is three to six months of treatment before surgery. Response rates are generally higher than with neoadjuvant tamoxifen, which is one reason aromatase inhibitors have become the preferred choice when neoadjuvant endocrine therapy is indicated.

Aromatase Inhibitors for Prevention

Beyond treating existing cancer, aromatase inhibitors have been tested for primary prevention in women at elevated risk of developing breast cancer. The results have been impressive. A systematic review for the U.S. Preventive Services Task Force found that aromatase inhibitors reduced the incidence of invasive breast cancer by about 55 percent in high-risk postmenopausal women, translating to about 16 fewer cases per 1,000 women over five years of use. That reduction was larger than what tamoxifen or raloxifene achieved in similar prevention trials.²²

Despite these numbers, aromatase inhibitors are not widely prescribed for prevention. Part of the reason is the side-effect burden described earlier. Another part is that the prevention trials have not yet shown a reduction in breast cancer deaths, only in diagnoses.²³ For a healthy woman considering a five-year course of daily medication with real side effects, knowing that the drug prevents some diagnoses but has not yet been shown to save lives makes the calculation genuinely difficult.

Aromatase Inhibitors in Men

Male breast cancer is rare, accounting for about one percent of all breast cancers. Most cases are hormone-receptor-positive, which makes endocrine therapy relevant. Tamoxifen has been the standard, and aromatase inhibitors have a more complicated role because men produce testosterone in the testes, and blocking aromatase alone may not fully suppress estrogen when the pituitary responds by driving more testosterone production.

In the metastatic setting, pooled data suggest that combining an aromatase inhibitor with a drug that shuts down testicular hormone production (a GnRH analogue) roughly triples the rate of clinical benefit compared with an aromatase inhibitor alone.²⁴ A case series reported partial responses in about a quarter of patients and stable disease in over half, with median overall survival of about 39 months.²⁵ Still, tamoxifen remains the more common choice in both the curative and metastatic settings for men.²⁶ The evidence base for aromatase inhibitors in male breast cancer is thin compared with the massive trials in women, and randomized data comparing the two approaches directly in men essentially do not exist.

Genetic Variation in Drug Response

The aromatase enzyme is encoded by a gene called CYP19A1, and natural variation in that gene may influence how well aromatase inhibitors work. In one analysis from the large BIG 1-98 trial, certain CYP19A1 gene variants were associated with breast-cancer-free interval in tamoxifen-treated patients and with musculoskeletal and bone side effects regardless of which drug was used.²⁷ This means that some people may metabolize these drugs differently, or the enzyme they target may have slightly different behavior, which could influence both efficacy and side effects.

This line of research has not yet produced clinical tools that oncologists routinely use when prescribing aromatase inhibitors. No genetic test is currently standard of care for deciding which aromatase inhibitor to choose or whether to extend therapy. But it is an area where future personalization of treatment length and drug selection may eventually emerge, especially as the costs of genetic profiling continue to drop.